Added to YB: 2019-08-21
Pitch date: 2019-08-21
ATXI [bullish]
Avenue Therapeutics, Inc.
-99.99%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
Market Cap
$573.5K
Pitch Price
$7.0K
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-0.02
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Avenue Therapeutics: Two-Step Merger with Cipla, CVR
ATXI: Avenue Therapeutics + Cipla 2-step merger. $6 now, $13.94 on FDA approval of IV Tramadol by 12/1/20. Tramadol is common, safe opioid pain drug. IV form approved ex-US, not in US yet. NDA submission soon. Binary outcome, favorable odds. CVR on $325M+ sales. Low float.
Read full article (4 min)